Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Community Practice Connections™: Exploring HER2/3-Targeted Treatment Approaches for Gastrointestinal Cancers

Release Date: March 31, 2020
Expiration Date: March 31, 2021

Activity Overview

This online education activity is designed to provide an expert overview of current and emerging data on HER2/3-targeted treatment of gastrointestinal (GI) cancers. This program includes information on the rationale for targeting HER2 and HER3 in GI cancers as well as testing techniques specific to these tumor types, current HER2-targeted treatment paradigms for esophagogastric and colorectal cancers, and novel HER2/3-targeted agents, including biosimilars and antibody-drug conjugates, under investigation for GI cancers. This activity is presented in a multimedia format that includes a series of video interviews with 2 expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of gastrointestinal (GI) cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with GI cancers are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain the rationale for the use of HER2/3-targeted therapies for the treatment of patients with GI malignancies
  • Evaluate molecular testing strategies for the detection of HER2/3 in GI malignancies
  • Assess data from clinical trials exploring HER2/3-targeted treatments for patients with GI malignancies
  • Apply HER2/3-targeted therapies in clinical practice for the treatment of patients with GI malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


David H. Ilson, MD, PhD
David H. Ilson, MD, PhD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Astellas, Taiho Oncology; Consultant: Amgen, AstraZeneca, Astellas Pharma, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Merck, Pieris Pharmaceuticals, Roche, Taiho Oncology.

Ryan B. Corcoran, MD, PhD
Ryan B. Corcoran, MD, PhD
Director, Gastrointestinal Cancer Center Program
Scientific Director, Henri and Belinda Termeer Center for Targeted Therapy
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Asana BioSciences, AstraZeneca, Eli Lilly and Company; Consultant: Array BioPharma, Avidity Biosciences, Astex, Bristol Myers Squibb, C4 Therapeutics, Elicio Therapeutics, Genentech, Kinnate Biopharma/Fount Therapeutics; Speakers Bureau: Guardant Health, N-of-One, Novartis, nRichDX, Revolution Medicines, Shionogi, Taiho Oncology; Shareholder: Avidity Biosciences, C4 Therapeutics, nRichDX, Revolution Medicines, Kinnate Biopharma/Fount Therapeutics.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By